Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving highly emetogenic chemotherapy (HEC)

Abstract only

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 32; no. 15_suppl; p. 9638
Main Authors:	Rapoport, Bernardo Leon, Poma, Allen, Hedley, Mary Lynne, Martell, Robert E., Navari, Rudolph M.
Format:	Journal Article
Language:	English
Published:	20-05-2014
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!